These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 28194593)

  • 1. Synchronous endometrial and ovarian carcinomas: predictors of risk and associations with survival and tumor expression profiles.
    Kelemen LE; Rambau PF; Koziak JM; Steed H; Köbel M
    Cancer Causes Control; 2017 May; 28(5):447-457. PubMed ID: 28194593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset.
    Garg K; Shih K; Barakat R; Zhou Q; Iasonos A; Soslow RA
    Am J Surg Pathol; 2009 Dec; 33(12):1869-77. PubMed ID: 19898223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of INPP4B protein immunohistochemistry in ovarian cancer.
    Salmena L; Shaw P; Fans I; McLaughlin ; Rosen B; Risch H; Mitchell C; Sun P; Narod SA; Kotsopoulos J
    Eur J Gynaecol Oncol; 2015; 36(3):260-7. PubMed ID: 26189250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significant frequency of MSH2/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype-specific Lynch syndrome screening in ovarian carcinomas.
    Rambau PF; Duggan MA; Ghatage P; Warfa K; Steed H; Perrier R; Kelemen LE; Köbel M
    Histopathology; 2016 Aug; 69(2):288-97. PubMed ID: 26799366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemistry expression of targeted therapies biomarkers in ovarian clear cell and endometrioid carcinomas (type I) and endometriosis.
    Barreta A; Sarian LO; Ferracini AC; Costa LBE; Mazzola PG; de Angelo Andrade L; Derchain S
    Hum Pathol; 2019 Mar; 85():72-81. PubMed ID: 30447298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.
    Sieh W; Köbel M; Longacre TA; Bowtell DD; deFazio A; Goodman MT; Høgdall E; Deen S; Wentzensen N; Moysich KB; Brenton JD; Clarke BA; Menon U; Gilks CB; Kim A; Madore J; Fereday S; George J; Galletta L; Lurie G; Wilkens LR; Carney ME; Thompson PJ; Matsuno RK; Kjær SK; Jensen A; Høgdall C; Kalli KR; Fridley BL; Keeney GL; Vierkant RA; Cunningham JM; Brinton LA; Yang HP; Sherman ME; García-Closas M; Lissowska J; Odunsi K; Morrison C; Lele S; Bshara W; Sucheston L; Jimenez-Linan M; Driver K; Alsop J; Mack M; McGuire V; Rothstein JH; Rosen BP; Bernardini MQ; Mackay H; Oza A; Wozniak EL; Benjamin E; Gentry-Maharaj A; Gayther SA; Tinker AV; Prentice LM; Chow C; Anglesio MS; Johnatty SE; Chenevix-Trench G; Whittemore AS; Pharoah PD; Goode EL; Huntsman DG; Ramus SJ
    Lancet Oncol; 2013 Aug; 14(9):853-62. PubMed ID: 23845225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas.
    Moreno-Bueno G; Gamallo C; Pérez-Gallego L; de Mora JC; Suárez A; Palacios J
    Diagn Mol Pathol; 2001 Jun; 10(2):116-22. PubMed ID: 11385321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary.
    Sato N; Tsunoda H; Nishida M; Morishita Y; Takimoto Y; Kubo T; Noguchi M
    Cancer Res; 2000 Dec; 60(24):7052-6. PubMed ID: 11156411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent Mismatch Repair Protein Deficiency in Mixed Endometrioid and Clear Cell Carcinoma of the Endometrium.
    Köbel M; Tessier-Cloutier B; Leo J; Hoang LN; Gilks CB; Soslow RA; Delair D; Stewart CJR; Lee CH
    Int J Gynecol Pathol; 2017 Nov; 36(6):555-561. PubMed ID: 28114191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor site discordance in mismatch repair deficiency in synchronous endometrial and ovarian cancers.
    Kim SR; Tone A; Kim R; Cesari M; Clarke B; Eiriksson L; Hart T; Aronson M; Holter S; Lytwyn A; Maganti M; Oldfield L; Gallinger S; Bernardini MQ; Oza AM; Djordjevic B; Lerner-Ellis J; Van de Laar E; Vicus D; Pugh TJ; Pollett A; Ferguson SE
    Int J Gynecol Cancer; 2020 Dec; 30(12):1951-1958. PubMed ID: 33082239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endometriosis does not confer improved prognosis in ovarian carcinoma of uniform cell type.
    Cuff J; Longacre TA
    Am J Surg Pathol; 2012 May; 36(5):688-95. PubMed ID: 22498820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L1CAM expression associates with poor outcome in endometrioid, but not in clear cell ovarian carcinoma.
    Soovares P; Pasanen A; Bützow R; Lassus H
    Gynecol Oncol; 2017 Sep; 146(3):615-622. PubMed ID: 28625395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
    Huang HN; Lin MC; Tseng LH; Chiang YC; Lin LI; Lin YF; Huang HY; Kuo KT
    Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors of synchronous endometrial and ovarian endometrioid carcinoma.
    Yoneoka Y; Yoshida H; Ishikawa M; Shimizu H; Uehara T; Murakami T; Kato T
    J Gynecol Oncol; 2019 Jan; 30(1):e7. PubMed ID: 30479091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoexpression of the PTEN protein and matrix metalloproteinase-2 in endometrial cysts, endometrioid and clear cell ovarian cancer.
    Brucka A; Szyłło K
    Ginekol Pol; 2013 May; 84(5):344-51. PubMed ID: 23819399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ARID1A, p53 and ß-Catenin statuses are strong prognosticators in clear cell and endometrioid carcinoma of the ovary and the endometrium.
    Heckl M; Schmoeckel E; Hertlein L; Rottmann M; Jeschke U; Mayr D
    PLoS One; 2018; 13(2):e0192881. PubMed ID: 29451900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
    Skírnisdóttir I; Seidal T
    Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis of women with stage I endometrioid endometrial cancer and synchronous stage I endometrioid ovarian cancer.
    Matsuo K; Machida H; Frimer M; Marcus JZ; Pejovic T; Roman LD; Wright JD
    Gynecol Oncol; 2017 Dec; 147(3):558-564. PubMed ID: 28986093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression of DNA mismatch repair protein in endometrial carcinomas and its correlation with clinicopathologic features].
    Bi R; Tu XY; Xiao YX; Shan BE; Wang HY; Cai X; Zhou XY; Yang WT
    Zhonghua Bing Li Xue Za Zhi; 2016 May; 45(5):302-7. PubMed ID: 27142910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Lynch syndrome-related endometrial carcinoma].
    Pang SJ; Guo DH
    Zhonghua Bing Li Xue Za Zhi; 2012 Jul; 41(7):494-7. PubMed ID: 22932468
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.